Warning #1: Bank of America sees transitory hyperinflation coming. Warning #2: there is nothing "transitory" about this.
Articles
Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders
Psychedelic stocks have become extremely concentrated -- like other sectors. Here's why we see that changing in this sector.
Red Light Holland Receives Patent Pending Status For 'Find Your Dose' Customization of Microdosing Kits Based on Biometric and Movement Data
Red Light Holland granted patent pending status for its 'Find Your Dose' microdosing kit.
MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics
MindMed commences "Project Angie": psychedelic drug R&D aimed at treating pain, involving psychedelics including LSD.
Mydecine Announces Partnership with LeadGen Labs
Mydecine announces a new partnership with LeadGen Labs, aimed at improving its drug synthesis operations.
Small Pharma Inc. to Commence Trading on the TSX Venture Exchange on May 6, 2021
UK-based Small Pharma Inc will commence trading on the TSX Venture Exchange (via RTO) on May 6, 2021, under the symbol "DMT".
Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics
Novamind is doubling its Cedar Psychiatry network from four to eight locations, estimating a 325% increase in patient visits.
Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in Houston; Locations of Next 5 Field Trip Health Centers ($FTRP, $FTRPF)
Field Trip announces the opening of its 5th new U.S. mental health clinic in Houston.
Optimi Health Partnership with Numinus Wellness Provides Update on First All-Natural Psilocybin Protocol
Optimi Health announces its product development agreement with Numinus Wellness is advancing toward a human trial.
Psyched Wellness Signs Supply Agreement for Amanita Muscaria
Psyched Wellness has contracted with a Lithuanian company to obtain 200 kgs of Amanita muscaria mushroom caps.
Mydecine Reports Full Year 2020 Financial Results and Provides Business Update
Mydecine reports that it's Phase IIa clinical trial is underway at three sites. Net loss for the year of CAD$26.9 million. Current cash ~CAD$30 million.
Minnesota Marijuana Legalization Bill Clears Another House Committee, For A Total Of Ten So Far
Another Minnesota House committee approved a bill to legalize marijuana on Saturday, raising the total number of panels that have advanced the proposal to 10.
Use of CBD May Be Associated With Reduced Alcohol Intake, New Study Shows
New research affiliated with the University of Colorado at Boulder and published in Psychology of Addictive Behaviors reveals that consumption of CBD-dominant cannabis may be associated with reduced alcohol intake.
The NEXT Psychedelic Stock To Uplist On The NASDAQ?
MindMed Inc has become the first psychedelics company to successfully uplist to the NASDAQ. Who will be the second...???
Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC
Numinus reports its Q2 2021 results. Cash balance of CAD$28.5 million. Net loss of CAD$4.2 million.